Lilly Affirms Immunology Interest with US$605 M ImmuNext Deal

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)

Published: 2 Apr-2019

DOI: 10.3833/pdr.v2019.i4.2414     ISSN: 1756-7874

Section: Research & Development



In another sign of its commitment to immunology, Eli Lilly has entered into a licensing and research collaboration with ImmuNext to develop immunometabolism therapies for the treatment of autoimmune diseases...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details